Clinical trial
A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV…
NCT00263666 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00263666 |
|---|---|
| Title | A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa |
| Official title | A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Reactogenicity and Immunogenicity of Three Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Rotavirus |
| Intervention type | Biological |
| Interventions | Rotarix, Placebo, Tritanrix-HB+Hib, Polio Sabin |
| Enrollment | 100 |
| Start date | Mar 16, 2005 |
| Primary completion | Feb 7, 2008 |
| Completion | Feb 13, 2008 |
| First posted | Dec 9, 2005 |
| Last update posted | Nov 23, 2020 |
| Countries | South Africa |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: